COMP <GO>
PODD vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Insulet Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PODD 9
— ABBV 6
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: PODD
LAST: $149.68 (-1.85%) • MKT CAP: $10.58B
options-implied-move
6.90%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PODD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PODD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.60% | 70.20% | +1.40 | PODD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.40% | 29.00% | -8.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.1x | 33.3x | -16.20 | PODD | /valuation <GO> |
| Free Cash Flow Yield | 3.57% | 3.47% | +0.10 | PODD | /fcf-yield <GO> |
| Operating Margin | 17.50% | 24.60% | -7.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 9.10% | 6.90% | +2.20 | PODD | /net-margins <GO> |
| Revenue Growth (YoY) | 30.70% | 8.60% | +22.10 | PODD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.72 | 5.33 | +0.39 | PODD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PODD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.90% | 7.40% | -0.50 | PODD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.4 | 72.8 | -10.43 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.15 | -0.16 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 113.1x | -77.10 | PODD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.58B | $513.86B | -$503.28B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PODD REV | ABBV REV | PODD GROSS % | ABBV GROSS % | PODD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.71B | $61.16B | 71.6% | 70.2% | $377.7M | $17.82B |
| FY 2024 | $2.07B | $56.33B | 69.8% | 70.0% | $305.3M | $17.83B |
| FY 2023 | $1.70B | $54.32B | 44.0% | 44.0% | $69.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PODD // BETA 0.99
ABBV // BETA 1.15